Replimune Group (NASDAQ:REPL) Sets New 1-Year High - Should You Buy?

Key Points

• Replimune shares reached a new 52-week high of $21.26 and were recently trading around $20.20, up 4.1%, with the stock well above its 50-day and 200-day moving averages.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and Leerink Partners raising its price target to $31. However, the consensus target of $14.33 is below the current share price, and two analysts maintain Sell ratings.
• The clinical-stage biotech beat quarterly EPS expectations, reporting a loss of $0.54 versus the expected $0.78 loss, but analysts forecast a full-year loss of $2.61 per share. Insiders have sold shares recently, while institutional investors own 92.53% of the company.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $21.26 and last traded at $20.2010, with a volume of 705,865 shares trading hands. The stock had previously closed at $19.49.

Wall Street Analyst Weigh In

REPL has been the subject of a number of recent research reports. Leerink Partners upped their target price on Replimune Group from $19.00 to $31.00 and gave the company an "outperform" rating in a research note on Thursday, October 29th. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, August 26th. Cantor Fitzgerald reissued an "overweight" rating on shares of Replimune Group in a report on Monday, October 5th. Piper Sandler upgraded shares of Replimune Group from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 31st. Finally, Weiss Ratings downgraded shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Replimune Group currently has an average rating of "Moderate Buy" and a consensus target price of $14.33.

Replimune Group Stock Up 4.1%

The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -7.32 and a beta of 0.93. The firm has a 50 day simple moving average of $13.67 and a 200-day simple moving average of $9.40. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.24. On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.61 EPS for the current fiscal year.

Insider Activity

In other news, CEO Sushil Patel sold 39,341 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the sale, the chief executive officer owned 708,151 shares of the company's stock, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the sale, the chief accounting officer directly owned 99,425 shares of the company's stock, valued at approximately $1,289,542.25. The trade was a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock valued at $1,038,364 in the last ninety days. 5.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in Replimune Group during the 3rd quarter worth about $64,000. Vise Technologies Inc. acquired a new stake in Replimune Group in the 3rd quarter valued at about $163,000. China Universal Asset Management Co. Ltd. increased its position in Replimune Group by 30.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company's stock valued at $223,000 after acquiring an additional 4,050 shares in the last quarter. Maxi Investments CY Ltd acquired a new stake in Replimune Group in the 3rd quarter valued at about $556,000. Finally, Opaleye Management Inc. bought a new position in shares of Replimune Group in the second quarter worth about $15,332,000. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company's approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.